アルツハイマー病治療薬の世界市場、2030年までの予測：製品別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界のアルツハイマー病治療薬市場は2023年に73億米ドルを占め、予測期間中のCAGRは10.1％で成長し、2030年には145億米ドルに達すると予測されています。

アルツハイマー病は、脳が萎縮し、脳細胞が死滅する神経疾患です。認知症の最も一般的な原因であり、思考力、行動力、社会性の継続的な低下を招き、人の自立能力に影響を与えます。この病気の初期症状には、最近の出来事や会話を忘れることが含まれます。

米国アルツハイマー協会誌によると、米国では65歳以上の高齢者の10.7％にあたる9人に1人がアルツハイマー型認知症です。

効果的な治療法への需要の高まり

世界人口の高齢化に伴い、アルツハイマー病の有病率は増加しており、その進行を遅らせたり、症状を緩和したりする治療に対する緊急の必要性が生じています。この需要により、新薬や治療法の開発に対する研究や投資が活発化しています。製薬会社は、このアンメット・メディカル・ニーズに対応するため、疾患修飾薬やプレシジョン・メディシンなどの革新的なアプローチを積極的に模索しています。さらに、アルツハイマー病患者のQOL（生活の質）を向上させることに重点を置くことで、支持療法製品・サービスの市場も活性化しており、ヘルスケア産業における有益かつ発展的な分野となっています。

アルツハイマー病治療薬の研究開発コストの高さ

アルツハイマー病に対する効果的な治療法の開発は、複雑で時間のかかるプロセスであり、多くの場合、長期の臨床試験と厳格な規制要件が含まれます。アルツハイマー病治療薬の開発における失敗率は著しく高く、成功が保証されないまま多額の資金を投資することになります。このような研究開発費の高騰は、製薬会社がアルツハイマー病治療薬の開発を進める意欲を削ぎ、潜在的な治療法の数を制限することになりかねないです。さらに、このような研究開発費は、結果として薬価の高騰を招き、患者やヘルスケアシステムにとって経済的な課題となる可能性があるため、重要な治療法へのアクセスをさらに妨げることになります。

精密医療や遺伝子治療などの革新的アプローチの開発

精密医療は、個人の遺伝的・分子的プロファイルに合わせた治療を行うもので、より効果的で個別化された治療につながる可能性があります。一方、遺伝子治療は、特定の遺伝子変異や異常タンパク質を標的とすることで、アルツハイマー病の根本原因に対処することを目的としています。これらの画期的な技術は、病気の経過を変化させる可能性を秘めており、予防と治療の両方に希望を与えるものです。これらの分野の研究が進むにつれて、より正確で、インパクトがあり、治癒の可能性のある介入が可能になる見込みであり、アルツハイマー病との闘いにおける重要な前進となります。

長く複雑な承認プロセス

アルツハイマー病の新薬の市場開拓は、多くの場合10年以上にも及ぶ、時間とリソースを要する取り組みです。大規模な臨床試験や厳格な安全性評価を含む厳しい規制要件は、承認に必要な時間とコストを著しく増大させる。アルツハイマー型認知症治療薬の開発における高い開発中止率は、この課題をさらに悪化させています。薬事承認取得の遅れは、製薬会社を躊躇させるだけでなく、患者の生命を変える可能性のある治療法へのアクセスを妨げることにもなります。

COVID-19の影響

COVID-19の大流行はアルツハイマー病市場に多面的な影響を与えました。一方では、新たなアルツハイマー病治療薬の開発を目指した臨床試験や研究努力が中断され、遅延や後退を引き起こしました。さらに、パンデミック対応に向けたヘルスケア資源の再配分は、アルツハイマー病患者に利用可能なケアとサポートを緊張させました。社会的孤立対策は、この脆弱な人々の認知機能の低下と精神衛生上の問題を悪化させました。一方、パンデミックは、アルツハイマー病患者に対する革新的な遠隔モニタリングと遠隔医療ソリューションの必要性を浮き彫りにしました。また、長期介護施設における備えの重要性も強調されました。

予測期間中、コリンエステラーゼ阻害剤セグメントが最大となる見込み

コリンエステラーゼ阻害薬セグメントは有利な成長が見込まれます。ドネペジル、リバスチグミン、ガランタミンなどの薬剤を含むこれらの薬剤は、脳内の神経伝達物質であるアセチルコリンのレベルを高めることで認知症状を緩和するように設計されています。これらの薬剤は記憶障害や認知障害を一時的に緩和し、アルツハイマー病患者の生活の質を向上させる。コリンエステラーゼ阻害薬は治療の主役であるが、治療薬ではないです。アルツハイマーの有病率の増加に伴い、この壊滅的な神経変性疾患に対するより効果的で的を絞った治療法を開発するための継続的な研究とともに、これらの薬剤の市場は成長を続けています。

ドラッグストア部門は予測期間中に最も高いCAGRが見込まれる

ドラッグストア分野は、予測期間中に最も速いCAGRの成長が見込まれます。これらの小売店では、アルツハイマー症状を管理するために一般的に処方されるコリンエステラーゼ阻害剤やメマンチンなどの医薬品を幅広く取り扱っています。さらに、ドラッグストアは、アルツハイマー病患者とその介護者にとって重要なサプリメントや医療用品などの市販品を提供しています。ドラッグストアは、アルツハイマー病の管理に関する情報やサポートを求める家族にとって、しばしば貴重な情報源となります。アルツハイマー病の有病率の上昇に伴い、ドラッグストアは、この患者集団のユニークなニーズに合わせた専門的なサービスや製品を提供することにますます注力しており、アルツハイマー病のケアと治療に大きく貢献しています。

最もシェアが高い地域

予測期間中、北米のアルツハイマー病治療薬市場は、ヘルスケア業界におけるダイナミックで急速に発展するセクターであるため、引き続き市場シェアの大半を占めると予想されます。同市場には、神経変性疾患の1つであるアルツハイマー病の管理・治療を目的とした医薬品、生物製剤、新興治療薬などが含まれます。高齢化人口の増加とアルツハイマー病に対する意識の高まりに伴い、市場は研究開発に多額の投資を行っています。主要企業は、アルツハイマー病の複雑な性質に対処するため、疾患修飾薬や精密医療を含む革新的なアプローチに取り組んでいます。

CAGRが最も高い地域：

予測期間中、アジア太平洋のCAGRが最も高いと予測されます。急速な高齢化とヘルスケアインフラの改善により、アルツハイマー病の有病率は上昇傾向にあります。日本、中国、韓国などの国々はアルツハイマー病治療の研究開発に多額の投資を行っており、医薬品市場の競争につながっています。しかし、診断の遅れ、認知度の低さ、地域によって異なるヘルスケアシステムなどの課題は依然として残っています。また、規制上のハードルや文化的な偏見も、患者のケアや革新的な治療法へのアクセスに影響を与えています。それにもかかわらず、アジア太平洋のアルツハイマー病市場は、公衆衛生上の懸念が高まる中、効果的な治療法に対する差し迫ったニーズによって、大きな成長の可能性を秘めています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

• 企業プロファイル
  • 追加市場企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査源
  • 1次調査源
  • 2次調査源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のアルツハイマー病治療薬市場：製品別

• コリンエステラーゼ阻害剤
  • ドネペジル
  • リバスチグミン
  • ガランタミン
• N-メチル-D-アスパラギン酸（NMDA）受容体拮抗薬
• 配合剤
• その他の製品

第6章 世界のアルツハイマー病治療薬市場：エンドユーザー別

• 病院薬局
• 小売薬局
• ドラッグストア
• オンライン薬局
• その他のエンドユーザー

第7章 世界のアルツハイマー病治療薬市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東・アフリカ

第8章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第9章 企業プロファイル

• Cipla Ltd.
• Daiichi Sankyo Company, Limited
• Dr. Reddy's Laboratories Ltd
• Amneal Pharmaceuticals Inc.
• Aurobindo Pharma Ltd
• AbbVie, Inc.
• Eisai Co., Ltd.
• Adamas Pharmaceuticals, Inc.
• F. Hoffmann La Roche Ltd.
• H. Lundbeck A/S
• Johnson & Johnson Services, Inc.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• TauRx Pharmaceuticals Ltd.
• Lannett Inc.
• Lupin Ltd
• Macleods Pharmaceuticals Ltd.

List of Tables

• Table 1 Global Alzheimer's Therapeutics Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 4 Global Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
• Table 5 Global Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
• Table 6 Global Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
• Table 7 Global Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
• Table 8 Global Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
• Table 9 Global Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 10 Global Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
• Table 11 Global Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 12 Global Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 13 Global Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 14 Global Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 15 Global Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 16 North America Alzheimer's Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 17 North America Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
• Table 18 North America Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 19 North America Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
• Table 20 North America Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
• Table 21 North America Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
• Table 22 North America Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
• Table 23 North America Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
• Table 24 North America Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 25 North America Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
• Table 26 North America Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 27 North America Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 28 North America Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 29 North America Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 30 North America Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 31 Europe Alzheimer's Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 32 Europe Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
• Table 33 Europe Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 34 Europe Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
• Table 35 Europe Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
• Table 36 Europe Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
• Table 37 Europe Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
• Table 38 Europe Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
• Table 39 Europe Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 40 Europe Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
• Table 41 Europe Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 42 Europe Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 43 Europe Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 44 Europe Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 45 Europe Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 46 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 47 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
• Table 48 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 49 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
• Table 50 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
• Table 51 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
• Table 52 Asia Pacific Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
• Table 53 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
• Table 54 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 55 Asia Pacific Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
• Table 56 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 57 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 58 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 59 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 60 Asia Pacific Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 61 South America Alzheimer's Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 62 South America Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
• Table 63 South America Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 64 South America Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
• Table 65 South America Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
• Table 66 South America Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
• Table 67 South America Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
• Table 68 South America Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
• Table 69 South America Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 70 South America Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
• Table 71 South America Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 72 South America Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 73 South America Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 74 South America Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 75 South America Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 76 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 77 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Product (2021-2030) ($MN)
• Table 78 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Cholinesterase Inhibitors (2021-2030) ($MN)
• Table 79 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Donepezil (2021-2030) ($MN)
• Table 80 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Rivastigmine (2021-2030) ($MN)
• Table 81 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Galantamine (2021-2030) ($MN)
• Table 82 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By N -Methyl-D-Aspartate (NMDA) Receptor Antagonists (2021-2030) ($MN)
• Table 83 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Combination Drug (2021-2030) ($MN)
• Table 84 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
• Table 85 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By End User (2021-2030) ($MN)
• Table 86 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 87 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 88 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 89 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 90 Middle East & Africa Alzheimer's Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Alzheimer's Therapeutics Market is accounted for $7.3 billion in 2023 and is expected to reach $14.5 billion by 2030 growing at a CAGR of 10.1% during the forecast period. Alzheimer's disease is a neurological disorder that causes the brain to shrink (atrophy) and brain cells to die. It is the most common cause of dementia that leads to continuous decline in thinking, behavioral and social skills that affects the ability of a person to function independently. The early signs of the disease include forgetting recent events or conversations.

According to the Journal of the Alzheimer's Association, In the United States, around 1 in 9 people which comprised 10.7% of the people aged 65 and older are having Alzheimer's dementia.

Market Dynamics:

Driver:

Growing demand for effective treatments

As the global population ages, the prevalence of Alzheimer's disease is increasing, creating a pressing need for therapies that can slow down its progression or alleviate its symptoms. This demand has spurred increased research and investment in the development of new drugs and therapies. Pharmaceutical companies are actively seeking innovative approaches, such as disease-modifying drugs and precision medicine, to address this unmet medical need. Additionally, the focus on improving the quality of life for Alzheimer's patients has driven the market for supportive care products and services, making it a lucrative and evolving sector in the healthcare industry.

Restraint:

High cost of research and development for Alzheimer's drugs

Developing effective treatments for Alzheimer's disease is an intricate and time-consuming process, often involving lengthy clinical trials and rigorous regulatory requirements. The failure rate in Alzheimer's drug development is notably high, leading to substantial financial investments without guaranteed success. These elevated R&D costs can discourage pharmaceutical companies from pursuing Alzheimer's drug development, limiting the number of potential treatments. Moreover, these expenses can subsequently result in high medication prices, which may pose affordability challenges for patients and healthcare systems, thus further hindering access to these crucial therapies.

Opportunity:

Development of innovative approaches such as precision medicine and gene therapy

Precision medicine tailors treatments to an individual's genetic and molecular profile, potentially leading to more effective and personalized therapies. Gene therapy, on the other hand, aims to address the root causes of Alzheimer's by targeting specific genetic mutations or aberrant proteins. These groundbreaking techniques hold the potential to modify the course of the disease, offering hope for both prevention and treatment. As research in these areas progresses, they offer the prospect of more precise, impactful, and potentially curative interventions, marking a significant step forward in the fight against Alzheimer's.

Threat:

The lengthy and complex regulatory approval process

Developing and bringing new Alzheimer's drugs to market is a time-consuming and resource-intensive endeavor, often spanning over a decade. The stringent regulatory requirements, including extensive clinical trials and rigorous safety evaluations, significantly extend the time and cost required for approval. The high attrition rate in Alzheimer's drug development further exacerbates this challenge. Delays in obtaining regulatory clearance not only deter pharmaceutical companies but also hinder patient access to potentially life-changing treatments.

COVID-19 Impact:

The COVID-19 pandemic has had a multifaceted impact on the Alzheimer's market. On one hand, it disrupted clinical trials and research efforts aimed at developing new Alzheimer's treatments, causing delays and setbacks. Additionally, the redirection of healthcare resources towards pandemic response strained the care and support available for Alzheimer's patients. Social isolation measures exacerbated cognitive decline and mental health issues among this vulnerable population. On the other hand, the pandemic highlighted the need for innovative remote monitoring and telehealth solutions for Alzheimer's patients. It also underscored the importance of preparedness in long-term care facilities.

The cholinesterase inhibitors segment is expected to be the largest during the forecast period

The cholinesterase inhibitors segment is expected to have lucrative growth. These medications, including drugs like Donepezil, Rivastigmine, and Galantamine, are designed to alleviate cognitive symptoms by enhancing the levels of acetylcholine, a neurotransmitter in the brain. They provide temporary relief from memory and cognitive impairments, improving the quality of life for Alzheimer's patients. Cholinesterase inhibitors have been a mainstay of treatment, though they do not offer a cure. With the increasing prevalence of Alzheimer's, the market for these drugs continues to grow, alongside ongoing research to develop more effective and targeted treatments for this devastating neurodegenerative disease.

The drug stores segment is expected to have the highest CAGR during the forecast period

The drug stores segment is anticipated to witness the fastest CAGR growth during the forecast period. These retail outlets offer a wide range of pharmaceuticals, including cholinesterase inhibitors and memantine, which are commonly prescribed to manage Alzheimer's symptoms. Additionally, drug stores provide over-the-counter products such as supplements and medical supplies, crucial for Alzheimer's patients and their caregivers. They often serve as a valuable resource for families seeking information and support for managing the disease. With the rising prevalence of Alzheimer's, drug stores are increasingly focused on providing specialized services and products tailored to the unique needs of this patient population, thus contributing significantly to Alzheimer's care and treatment.

Region with largest share:

During the forecast period, it is expected that the North America Alzheimer's Therapeutics market will continue to hold a majority of the market share due to its dynamic and rapidly evolving sector within the healthcare industry. It encompasses a range of pharmaceuticals, biologics, and emerging therapies aimed at managing and treating Alzheimer's disease, a prevalent neurodegenerative condition. With a growing aging population and increasing awareness of Alzheimer's, the market is witnessing significant investments in research and development. Key players are working on innovative approaches, including disease-modifying drugs and precision medicine, to address the complex nature of Alzheimer's.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. With a rapidly aging population and improving healthcare infrastructure, the prevalence of Alzheimer's is on the rise. Countries like Japan, China, and South Korea are investing heavily in research and development for Alzheimer's treatments, leading to a competitive pharmaceutical market. However, challenges such as underdiagnosis, limited awareness, and varying healthcare systems across the region persist. Regulatory hurdles and cultural stigmas also impact patient care and access to innovative therapies. Nonetheless, the Asia Pacific Alzheimer's market holds significant growth potential, driven by a pressing need for effective treatments in the face of this escalating public health concern.

Key players in the market:

Some of the key players in Alzheimer's Therapeutics Market include: Cipla Ltd., Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd, Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd, AbbVie, Inc., Eisai Co., Ltd., Adamas Pharmaceuticals, Inc., F. Hoffmann La Roche Ltd., H. Lundbeck A/S, Johnson & Johnson Services, Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., TauRx Pharmaceuticals Ltd., Lannett Inc., Lupin Ltd and Macleods Pharmaceuticals Ltd.

Key Developments:

In March 2023, Biogen Inc. and Eisai Co., expanded their collaboration to find therapeutics treatments of the disease.

In December 2022, Kashiv Specialty Pharmaceuticals is acquired by Amneal. Amneal obtained access to the pipeline of complex generics and branded 505(b)2 medicines through this arrangement.

In May 2022, Amneal completed the acquisition of Kashiv Specialty Pharmaceuticals. Through this acquisition, Amneal gained the pipeline of 505(b)2 branded products and complex generics.

Products Covered:

• Cholinesterase Inhibitors
• N -Methyl-D-Aspartate (NMDA) Receptor Antagonists
• Combination Drug
• Other Products

End Users Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Alzheimer's Therapeutics Market, By Product

• 5.1 Introduction
• 5.2 Cholinesterase Inhibitors
  • 5.2.1 Donepezil
  • 5.2.2 Rivastigmine
  • 5.2.3 Galantamine
• 5.3 N -Methyl-D-Aspartate (NMDA) Receptor Antagonists
• 5.4 Combination Drug
• 5.5 Other Products

6 Global Alzheimer's Therapeutics Market, By End User

• 6.1 Introduction
• 6.2 Hospital Pharmacies
• 6.3 Retail Pharmacies
• 6.4 Drug Stores
• 6.5 Online Pharmacies
• 6.6 Other End Users

7 Global Alzheimer's Therapeutics Market, By Geography

• 7.1 Introduction
• 7.2 North America
  • 7.2.1 US
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Italy
  • 7.3.4 France
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 New Zealand
  • 7.4.6 South Korea
  • 7.4.7 Rest of Asia Pacific
• 7.5 South America
  • 7.5.1 Argentina
  • 7.5.2 Brazil
  • 7.5.3 Chile
  • 7.5.4 Rest of South America
• 7.6 Middle East & Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 UAE
  • 7.6.3 Qatar
  • 7.6.4 South Africa
  • 7.6.5 Rest of Middle East & Africa

8 Key Developments

• 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 8.2 Acquisitions & Mergers
• 8.3 New Product Launch
• 8.4 Expansions
• 8.5 Other Key Strategies

9 Company Profiling

• 9.1 Cipla Ltd.
• 9.2 Daiichi Sankyo Company, Limited
• 9.3 Dr. Reddy's Laboratories Ltd
• 9.4 Amneal Pharmaceuticals Inc.
• 9.5 Aurobindo Pharma Ltd
• 9.6 AbbVie, Inc.
• 9.7 Eisai Co., Ltd.
• 9.8 Adamas Pharmaceuticals, Inc.
• 9.9 F. Hoffmann La Roche Ltd.
• 9.10 H. Lundbeck A/S
• 9.11 Johnson & Johnson Services, Inc.
• 9.12 Novartis AG
• 9.13 Sun Pharmaceutical Industries Ltd.
• 9.14 TauRx Pharmaceuticals Ltd.
• 9.15 Lannett Inc.
• 9.16 Lupin Ltd
• 9.17 Macleods Pharmaceuticals Ltd.